Recent progress in the area of ulcer and gastritis is still dominated by findings and reports on Helicobacter pylori and nonsteroidal anti-inflammatory drugs, which in turn are the two major causes of peptic ulcers. Although the prevalence of H. pylori is declining in most developed countries, it is still contributing to a significant proportion of peptic ulcers globally. The interrelationship of H. pylori gastritis in patients with gastroesophageal reflux has become more apparent. H. pylori-induced gastric body gastritis is associated with reduced acid production, and thus with reduced reflux and esophagitis. The controversies regarding the interactions between H. pylori and NSAIDs have still not been settled. With the availability of the new COX-2-specific inhibitors, the current scenario of NSAID-related gastroduodenal complications will certainly change. Short-term usage of these agents has significantly reduced the incidence of endoscopic ulcers, but the benefits in terms of clinical outcomes, such as bleeding or perforation, remain to be determined. This review summarizes the recent literature on peptic ulcer and gastritis.
References
-
1
Vaira D, Malfertheiner P, Megraud F, et al.
Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. HpSA European Study Group.
Lancet.
1999;
354
30-33
-
2
Graham D Y.
Therapy of Helicobacter pylori: current status and issues.
Gastroenterology.
2000;
118
S2-S8
-
3
Gisbert J P, Gisbert J L, Marcos S, et al.
Seven-day “rescue” therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole.
Aliment Pharmacol Ther.
1999;
13
1311-1316
-
4
Rinaldi V, Zullo A, de Francesco V, et al.
Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy.
Aliment Pharmacol Ther.
1999;
13
163-168
-
5
Lee J M, Breslin N P, Hyde D K, et al.
Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.
Aliment Pharmacol Ther.
1999;
13
489-496
-
6
Perri F, Festa V, Clemente R, et al.
Rifabutin-based “rescue therapy” for Helicobacter pylori infected patients after failure of standard regimens.
Aliment Pharmacol Ther.
2000;
14
311-316
-
7
Chan F K, Sung J J, Suen R, et al.
Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies.
Aliment Pharmacol Ther.
2000;
14
91-95
-
8
Yamaoka Y, Kodama T, Gutierrez O, et al.
Relationship between Helicobacter pylori iceA, cagA, and vacA status and clinical outcome: studies in four different countries.
J Clin Microbiol.
1999;
37
2274-2279
-
9
Yamaoka Y, Kodama T, Kita M, et al.
Relation between clinical presentation, Helicobacter pylori density, interleukin-1β and 8 production, and cagA status.
Gut.
1999;
45
804-811
-
10
Graham D Y, Osato M S.
H. pylori in the pathogenesis of duodenal ulcer: interaction between duodenal acid load, bile, and H. pylori.
Am J Gastroenterol.
2000;
95
87-91
-
11
Bodger K, Eastwood P G, Manning S I, et al.
Dyspepsia workload in urban general practice and implications of the British Society of Gastroenterology Dyspepsia guidelines (1996).
Aliment Pharmacol Ther.
2000;
14
413-420
-
12
Blum A L, Talley N J, O'Morain C, et al.
Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia: omeprazole plus clarithromycin and amoxicillin effect one year after treatment (OCAY) study group.
N Engl J Med.
1998;
339
1875-1881
-
13
Talley N J, Vakil N, Ballard ED I I, Fennerty M B.
Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia.
N Engl J Med.
1999;
341
1106-1111
-
14
McColl K, Murray L, el-Omar E, et al.
Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia.
N Engl J Med.
1998;
339
1869-1874
-
15
Jaakkimainen R L, Boyle E, Tudiver F.
Is Helicobacter pylori associated with non-ulcer dyspepsia and will eradication improve symptoms? A meta-analysis.
Br Med J.
1999;
319
1040-1044
-
16
Miwa H, Hirai S, Nagahara A, et al.
Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients: a double-blind placebo-controlled study.
Aliment Pharmacol Ther.
2000;
14
317-324
-
17
Moayyedi P, Feltbower R, Brown J, et al.
Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Leeds HELP Study Group.
Lancet.
2000;
355
1665-1669
-
18
Moayyedi P, Forman D, Braunholtz D, et al.
The proportion of upper gastrointestinal symptoms in the community associated with Helicobacter pylori, lifestyle factors, and nonsteroidal anti-inflammatory drugs. Leeds HELP Study Group.
Am J Gastroenterol.
2000;
95
1448-1455
-
19
Sobala G M, Crabtree J E, Pentith J A, et al.
Screening dyspepsia by serology to Helicobacter pylori.
Lancet.
1991;
338
94-96
-
20
Heaney A, Collins J S, Watson R G, et al.
A prospective randomised trial of a “test and treat” policy versus endoscopy based management in young Helicobacter pylori positive patients with ulcer-like dyspepsia, referred to a hospital clinic.
Gut.
1999;
45
186-190
-
21
Lassen A T, Pedersen F M, Bytzer P, et al.
Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial.
Lancet.
2000;
356
455-460
-
22
Graham D Y.
Can therapy ever be denied for Helicobacter pylori infection?.
Gastroenterology.
1997;
113
S113-117
-
23
Ciociola A A, McSorley D J, Turner K, et al.
Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated.
Am J Gastroenterol.
1999;
94
1834-1840
-
24
Lee J M, Breslin N P, Fallon C, O'Morain C A.
Rapid urease tests lack sensitivity in Helicobacter pylori diagnosis when peptic ulcer disease presents with bleeding.
Am J Gastroenterol.
2000;
95
1166-1170
-
25
Tu T C, Lee C L, Wu C H, et al.
Comparison of invasive and noninvasive tests for detecting Helicobacter pylori infection in bleeding peptic ulcers.
Gastrointest Endosc.
1999;
49
302-306
-
26
Graham D Y, Genta R, Evans D G, et al.
Helicobacter pylori does not migrate from the antrum to the corpus in response to omeprazole.
Am J Gastroenterol.
1996;
91
2120-2124
-
27
Sung J J, Lin S R, Ching J Y, et al.
Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study.
Gastroenterology.
2000;
119
7-14
-
28
Nardone G, Staibano S, Rocco A, et al.
Effect of Helicobacter pylori infection and its eradication on cell proliferation, DNA status, and oncogene expression in patients with chronic gastritis.
Gut.
1999;
44
789-799
-
29
El-Zimaity H M, Graham D Y.
Evaluation of gastric mucosal biopsy site and number for identification of Helicobacter pylori or intestinal metaplasia: role of the Sydney System.
Hum Pathol.
1999;
3
72-77
-
30
Kuipers E J, Lundell L, Klinkenberg-Knol E C, et al.
Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication.
N Engl J Med.
1996;
334
1018-1022
-
31
Klinkenberg-Knol E C, Nelis F, Dent J, et al.
Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa.
Gastroenterology.
2000;
118
661-669
-
32
Schenk B E, Kuipers E J, Nelis G F, et al.
Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy.
Gut.
2000;
46
615-621
-
33
Lamberts R, Creutzfeldt W, Struber H G, et al.
Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis.
Gastroenterology.
1993;
104
1356-1370
-
34
Meining A, Kiel G, Stolte M.
Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease.
Aliment Pharmacol Ther.
1998;
12
735-740
-
35
Stolte M, Bethke B.
Elimination of Helicobacter pylori under treatment with omeprazole.
Z Gastroenterol.
1990;
28
271-274
-
36
Klinkenberg-Knol E C, Festen H P, Jansen J B, et al.
Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety.
Ann Intern Med.
1994;
121
161-167
-
37
Meining A, Bosseckert H, Caspary W F, et al.
H2-receptor antagonists and antacids have an aggravating effect on Helicobacter pylori gastritis in duodenal ulcer patients.
Aliment Pharmacol Ther.
1997;
11
729-734
-
38
El-Serag H B, Sonnenberg A, Jamal M M, et al.
Corpus gastritis is protective against reflux oesophagitis.
Gut.
1999;
45
181-185
-
39
Wu J C, Sung J J, Chan F K, et al.
Helicobacter pylori infection is associated with milder gastro-oesophageal reflux disease.
Aliment Pharmacol Ther.
2000;
14
427-432
-
40
Anand B S, Graham D Y.
Ulcer and gastritis.
Endoscopy.
1999;
31
215-225
-
41
Aalykke C, Lauritsen J M, Hallas J, et al.
Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: a case-control study.
Gastroenterology.
1999;
116
1305-1309
-
42
Santolaria S, Lanas A, Benito R, et al.
Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users.
Aliment Pharmacol Ther.
1999;
13
1511-1518
-
43
Ng T M, Fock K M, Khor J L, et al.
Non-steroidal anti-inflammatory drugs, Helicobacter pylori and bleeding gastric ulcer.
Aliment Pharmacol Ther.
2000;
14
203-209
-
44
Weil J, Langman M J, Wainwright P, et al.
Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs.
Gut.
2000;
46
27-31
-
45
Cryer B, Feldman M.
Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans.
Gastroenterology.
1999;
117
17-25
-
46
Patrono C, Ciabattoni G, Patrignani P, et al.
Clinical pharmacology of platelet cyclooxygenase inhibition.
Circulation.
1985;
72
1177-1784
-
47
Dutch TIA Trial Study G roup.
A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke.
N Engl J Med.
1991;
325
1261-1266
-
48
Kallmann R, Nieuwenhuis H K, de Groot P G, et al.
Effects of low doses of aspirin, 10 mg and 30 mg daily, on bleeding time, thromboxane production and 6-keto-PGF1 alpha excretion in healthy subjects.
Thromb Res.
1987;
45
355-361
-
49
Hoffmann W, Nitschke M, Muche J, et al.
Reevaluation of the Cottbus Reinfarction Study with 30 mg aspirin per day 4 years after the end of the study.
Prostaglandins Leukot Essent Fatty Acids.
1991;
42
137-139
-
50
Hoffman W, Forster W.
Two year Cottbus reinfarction study with 30 mg aspirin per day.
Prostaglandins Leukot Essent Fatty Acids.
1991;
44
159-169
-
51
Muller P, Dammann H G, Marinis E, Simon B.
Gastrointestinal tolerance of 30 mg versus 300 mg acetylsalicylic acid daily: an endoscopically controlled double-blind study of healthy subjects.
Med Klin.
1990;
85
429-431
-
52
Graham D Y, Moon N.
Low-dose aspirin may or may not damage the gastric mucosa [letter].
Gastroenterology.
1999;
117
1505
-
53
Simon L S, Weaver A L, Graham D Y, et al.
Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
JAMA.
1999;
282
1921-1928
-
54
Laine L, Harper S, Simon T, et al.
A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group.
Gastroenterology.
1999;
117
776-783
-
55
Hawkey C, Laine L, Simon T, et al.
Comparison of the effect of rofecoxib (a cyclooxygenase-2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group.
Arthritis Rheum.
2000;
43
370-377
-
56
Langman M J, Jensen D M, Watson D J, et al.
Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
JAMA.
1999;
282
1929-1933
D. Y. Graham
Digestive Diseases Section, Rm 3A-320
Medical Center (111D)
2002 Holcombe Blvd
Houston, TX 77 030
USA
Fax: Fax:+ 1-713-790-1040
Email: E-mail:dgraham@bcm.tmc.edu
